DiaMedica Therapeutics (DMAC) Current Assets (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Current Assets for 10 consecutive years, with $44.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 42.59% year-over-year to $44.3 million; the trailing twelve-month figure through Jun 2026 stood at $44.3 million (up 42.59% YoY), and the FY2025 full-year result was $60.6 million, up 35.91% from the prior year.
• Current Assets declined to $44.3 million in Q2 2026 per DMAC's latest filing, from $52.4 million in the prior quarter.
• Across five years, Current Assets topped out at $60.6 million in Q4 2025 and bottomed at $29.7 million in Q1 2023.
• Historically, Current Assets has averaged $44.7 million across 5 years, with a median of $44.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Assets jumped 81.11% in 2022, then tumbled 43.51% in 2025.
• Over 5 years, Current Assets stood at $33.8 million in 2022, then jumped by 58.64% to $53.7 million in 2023, then dropped by 16.89% to $44.6 million in 2024, then jumped by 35.91% to $60.6 million in 2025, then slipped by 26.91% to $44.3 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $44.3 million, $52.4 million, and $60.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.